Hepatitis Monthly

Published by: Kowsar

Association Between ABCB1 (MDR1) Gene Polymorphism and Unresponsiveness Combined Therapy in Chronic Hepatitis C virus

Meryem Timucin 1 , Hakan Alagozlu 1 , Semra Ozdemir 2 and Ozturk Ozdemir 3 , 4 , *
Authors Information
1 Department of Gastroenterology, Faculty of Medicine, Cumhuriyet University, Sivas, Turkey
2 Department of Nuclear Medicine, Faculty of Medicine, Canakkale Onsekiz Mart University, Canakkale, Turkey
3 Department of Medical Genetics, Faculty of Medicine, Cumhuriyet University, Sivas, Turkey
4 Department of Medical Genetics, Faculty of Medicine, Canakkale Onsekiz Mart University, Canakkale, Turkey
Article information
  • Hepatitis Monthly: April 01, 2013, 13 (4); e7522
  • Published Online: April 13, 2013
  • Article Type: Research Article
  • Received: July 30, 2012
  • Revised: December 31, 2012
  • Accepted: January 31, 2013
  • DOI: 10.5812/hepatmon.7522

To Cite: Timucin M, Alagozlu H, Ozdemir S, Ozdemir O. Association Between ABCB1 (MDR1) Gene Polymorphism and Unresponsiveness Combined Therapy in Chronic Hepatitis C virus, Hepat Mon. 2013 ;13(4):e7522. doi: 10.5812/hepatmon.7522.

Abstract
Copyright © 2013, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Gross JB. Nonresponders to Previous Chronic Hepatitis C Treatment. Curr Treat Options Gastroenterol. 2004; 7(6): 469-75[PubMed]
  • 2. Chevaliez S, Hezode C, Soulier A, Costes B, Bouvier-Alias M, Rouanet S, et al. High-dose pegylated interferon-alpha and ribavirin in nonresponder hepatitis C patients and relationship with IL-28B genotype (SYREN trial). Gastroenterology. 2011; 141(1): 119-27[DOI][PubMed]
  • 3. Fidock MD, Souberbielle BE, Laxton C, Rawal J, Delpuech-Adams O, Corey TP, et al. The innate immune response, clinical outcomes, and ex vivo HCV antiviral efficacy of a TLR7 agonist (PF-4878691). Clin Pharmacol Ther. 2011; 89(6): 821-9[DOI][PubMed]
  • 4. Böckle BC, Sepp NT. Hepatitis C virus and autoimmunity. Autoimmunity Highlights. 2010; 1(1): 23-35[DOI]
  • 5. Chary A, Holodniy M. Recent advances in hepatitis C virus treatment: review of HCV protease inhibitor clinical trials. Rev Recent Clin Trials. 2010; 5(3): 158-73[PubMed]
  • 6. Della Rossa A, Tavoni A, Baldini C, Bombardieri S. Mixed cryoglobulinemia and hepatitis C virus association: ten years later. Isr Med Assoc J. 2001; 3(6): 430-4[PubMed]
  • 7. McMurray RW. HEPATITIS C–ASSOCIATED AUTOIMMUNE DISORDERS. Rheum Dis Clin North Am. 1998; 24(2): 353-74[DOI]
  • 8. Muhammad D, Anjum A, AMIN K, Javed M. Chronic Hepatitis C Virus İnfection; Associated with Type 2 Diabetes Mellitus. Proffesional Med J. 2010; 17(4): 557-62
  • 9. Scotto G, Cibelli DC, Saracino A, Prato R, Palumbo E, Fazio V, et al. Cryoglobulinemia in subjects with HCV infection alone, HIV infection and HCV/HIV coinfection. J Infect. 2006; 52(4): 294-9[DOI][PubMed]
  • 10. Potthoff A, Witte T, Rifai K, Hoy L, Deterding K, Feyerabend S, et al. Prevalence of alpha-fodrin antibodies in patients with chronic hepatitis C infection and Sjogren syndrome. Scand J Gastroenterol. 2009; 44(8): 994-1003[DOI][PubMed]
  • 11. Syed GH, Amako Y, Siddiqui A. Hepatitis C virus hijacks host lipid metabolism. Trends Endocrinol Metab. 2010; 21(1): 33-40[DOI][PubMed]
  • 12. Fukasawa M. Cellular lipid droplets and hepatitis C virus life cycle. Biol Pharm Bull. 2010; 33(3): 355-9[PubMed]
  • 13. El-Satar HA, Mahfouz M, Rashed L, Ahmet D. Insulin Resistance in patients with chronic hepatitis c Infection. Aust J Basic Appl Sci. 2010; 4(10): 4554-8
  • 14. Furutani M, Nakashima T, Sumida Y, Hirohama A, Yoh T, Kakisaka Y, et al. Insulin resistance/beta-cell function and serum ferritin level in non-diabetic patients with hepatitis C virus infection. Liver Int. 2003; 23(4): 294-9[PubMed]
  • 15. Negro F. Hepatitis C virus-induced steatosis: an overview. Dig Dis. 2010; 28(1): 294-9[DOI][PubMed]
  • 16. Kawaguchi T, Sata M. Importance of hepatitis C virus-associated insulin resistance: therapeutic strategies for insulin sensitization. World J Gastroenterol. 2010; 16(16): 1943-52[PubMed]
  • 17. Masgala A, Bonovas S, Nikolopoulos GK. Recent advances in the treatment of HIV/HBV and HIV/HCV co-infection. Mini Rev Med Chem. 2012; 12(9): 890-904[PubMed]
  • 18. Hong XL, Cao H, Zhao F, Pan XF, Zhang K, Xu QH, et al. [MiR-196a-2 gene polymorphism and the antiviral therapy of chronic hepatitis C]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2010; 24(6): 470-2[PubMed]
  • 19. Rizza SA, Cummins NW, Rider DN, Saeed S, Klein MB, Badley AD. Polymorphism in tumor necrosis factor-related apoptosis-inducing ligand receptor 1 is associated with poor viral response to interferon-based hepatitis C virus therapy in HIV/hepatitis C virus-coinfected individuals. AIDS. 2010; 24(17): 2639-44[DOI][PubMed]
  • 20. Sanabani SS, Nukui Y, Pereira J, da Costa AC, de Oliveira AC, Pessoa R, et al. Lack of evidence to support the association of a single IL28B genotype SNP rs12979860 with the HTLV-1 clinical outcomes and proviral load. BMC Infect Dis. 2012; 12: 374[DOI][PubMed]
  • 21. Mease K, Sane R, Podila L, Taub ME. Differential selectivity of efflux transporter inhibitors in Caco-2 and MDCK-MDR1 monolayers: a strategy to assess the interaction of a new chemical entity with P-gp, BCRP, and MRP2. J Pharm Sci. 2012; 101(5): 1888-97[DOI][PubMed]
  • 22. Uhr M, Tontsch A, Namendorf C, Ripke S, Lucae S, Ising M, et al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron. 2008; 57(2): 203-9[DOI][PubMed]
  • 23. Gumus-Akay G, Rustemoglu A, Karadag A, Sunguroglu A. Genotype and allele frequencies of MDR1 gene C1236T polymorphism in a Turkish population. Genet Mol Res. 2008; 7(4): 1193-9[PubMed]
  • 24. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, et al. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science. 2007; 315(5811): 525-8[DOI][PubMed]
  • 25. Maraz A, Furak J, Palfoldi R, Eller J, Szanto E, Kahan Z, et al. Roles of BCL-2 and MDR1 expression in the efficacy of paclitaxel-based lung cancer chemoradiation. Anticancer Res. 2011; 31(4): 1431-6[PubMed]
  • 26. Deenik W, van der Holt B, Janssen JJ, Chu IW, Valk PJ, Ossenkoppele GJ, et al. Polymorphisms in the multidrug resistance gene MDR1 (ABCB1) predict for molecular resistance in patients with newly diagnosed chronic myeloid leukemia receiving high-dose imatinib. Blood. 2010; 116(26): 6144-5[DOI][PubMed]
  • 27. Kikuchi R, McCown M, Olson P, Tateno C, Morikawa Y, Katoh Y, et al. Effect of hepatitis C virus infection on the mRNA expression of drug transporters and cytochrome p450 enzymes in chimeric mice with humanized liver. Drug Metab Dispos. 2010; 38(11): 1954-61[DOI][PubMed]
  • 28. Nakamura T, Sakaeda T, Horinouchi M, Tamura T, Aoyama N, Shirakawa T, et al. Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin Pharmacol Ther. 2002; 71(4): 297-303[DOI][PubMed]
  • 29. Ozen F, Silan C, Uludag A, Candan F, Silan F, Ozdemir S, et al. Association between ABCB1 (MDR1) gene 3435 C>T polymorphism and colchicine unresponsiveness of FMF patients. Ren Fail. 2011; 33(9): 899-903[DOI][PubMed]
  • 30. Eicher C, Dewerth A, Kirchner B, Warmann SW, Fuchs J, Armeanu-Ebinger S. Development of a drug resistance model for hepatoblastoma. Int J Oncol. 2011; 38(2): 447-54[DOI][PubMed]
  • 31. Lin CC, Hwang JM, Tsai MT, Su WW, Chen LM, Lai TY, et al. Protein kinase C alpha location and the expression of phospho-MEK and MDR1 in hepatitis virus-related hepatocellular carcinoma biopsies. Chin J Physiol. 2010; 53(2): 112-8[PubMed]
  • 32. Ling X, Zhou Y, Li SW, Yan B, Wen L. Modulation of mitochondrial permeability transition pore affects multidrug resistance in human hepatocellular carcinoma cells. Int J Biol Sci. 2010; 6(7): 773-83[PubMed]
  • 33. Park BL, Kim YJ, Cheong HS, Kim LH, Choi YH, Lee HS, et al. Association of common promoter polymorphisms of MCP1 with hepatitis B virus clearance. Exp Mol Med. 2006; 38(6): 694-702[PubMed]
  • 34. Nishanth RP, Ramakrishna BS, Jyotsna RG, Roy KR, Reddy GV, Reddy PK, et al. C-Phycocyanin inhibits MDR1 through reactive oxygen species and cyclooxygenase-2 mediated pathways in human hepatocellular carcinoma cell line. Eur J Pharmacol. 2010; 649(1-3): 74-83[DOI][PubMed]
  • 35. Sun Z, Zhao Z, Li G, Dong S, Huang Z, Ye L, et al. Relevance of two genes in the multidrug resistance of hepatocellular carcinoma: in vivo and clinical studies. Tumori. 2010; 96(1): 90-6[PubMed]
  • 36. Zhou Y, Ling XL, Li SW, Li XQ, Yan B. Establishment of a human hepatoma multidrug resistant cell line in vitro. World J Gastroenterol. 2010; 16(18): 2291-7[PubMed]
  • 37. Achari C, Reddy GV, Reddy TC, Reddanna P. Chebulagic acid synergizes the cytotoxicity of doxorubicin in human hepatocellular carcinoma through COX-2 dependant modulation of MDR-1. Med Chem. 2011; 7(5): 432-42[PubMed]
  • 38. Ros JE, Libbrecht L, Geuken M, Jansen PL, Roskams TA. High expression of MDR1, MRP1, and MRP3 in the hepatic progenitor cell compartment and hepatocytes in severe human liver disease. J Pathol. 2003; 200(5): 553-60[DOI][PubMed]
  • 39. Funaoka Y, Sakamoto N, Suda G, Itsui Y, Nakagawa M, Kakinuma S, et al. Analysis of interferon signaling by infectious hepatitis C virus clones with substitutions of core amino acids 70 and 91. J Virol. 2011; 85(12): 5986-94[DOI][PubMed]
  • 40. Engin A, Koksal B, Dogan T, Elaldı N, Dokmetas I, Bakır M, et al. Cytochrome P450 2D6 and MDR1 gene mutation in relation to mortality in patients with crimean-congo hemorrhagic fever: A preliminary study. Turkiye Klinikleri J Med Sci. 2009; 29(4): 905-10
  • 41. Galle F, Sanguinetti M, Colella G, Di Onofrio V, Torelli R, Rossano F, et al. Oral candidosis: characterization of a sample of recurrent infections and study of resistance determinants. New Microbiol. 2011; 34(4): 379-89[PubMed]
  • 42. Purkait B, Kumar A, Nandi N, Sardar AH, Das S, Kumar S, et al. Mechanism of amphotericin B resistance in clinical isolates of Leishmania donovani. Antimicrob Agents Chemother. 2012; 56(2): 1031-41[DOI][PubMed]
  • 43. Kato T, Fujita Y, Nakane K, Kojima T, Nozawa Y, Deguchi T, et al. ETS1 promotes chemoresistance and invasion of paclitaxel-resistant, hormone-refractory PC3 prostate cancer cells by up-regulating MDR1 and MMP9 expression. Biochem Biophys Res Commun. 2012; 417(3): 966-71[DOI][PubMed]
  • 44. Rein DT, Volkmer A, Bauerschmitz G, Beyer IM, Janni W, Fleisch MC, et al. Combination of a MDR1-targeted replicative adenovirus and chemotherapy for the therapy of pretreated ovarian cancer. J Cancer Res Clin Oncol. 2012; 138(4): 603-10[DOI][PubMed]
  • 45. Rein DT, Volkmer A, Beyer IM, Curiel DT, Janni W, Dragoi A, et al. Treatment of chemotherapy resistant ovarian cancer with a MDR1 targeted oncolytic adenovirus. Gynecol Oncol. 2011; 123(1): 138-46[DOI][PubMed]
  • 46. Yan PW, Huang XE, Yan F, Xu L, Jiang Y. Influence of MDR1 gene codon 3435 polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancer. Asian Pac J Cancer Prev. 2011; 12(9): 2291-4[PubMed]
  • 47. Zhou Y, Sridhar R, Shan L, Sha W, Gu X, Sukumar S. Loperamide, an FDA-approved antidiarrhea drug, effectively reverses the resistance of multidrug resistant MCF-7/MDR1 human breast cancer cells to doxorubicin-induced cytotoxicity. Cancer Invest. 2012; 30(2): 119-25[DOI][PubMed]
  • 48. Hoofnagle JH, Wahed AS, Brown RS, Jr., Howell CD, Belle SH. Early changes in hepatitis C virus (HCV) levels in response to peginterferon and ribavirin treatment in patients with chronic HCV genotype 1 infection. J Infect Dis. 2009; 199(8): 1112-20[DOI][PubMed]
  • 49. Artini M, Natoli C, Tinari N, Costanzo A, Marinelli R, Balsano C, et al. Elevated serum levels of 90K/MAC-2 BP predict unresponsiveness to alpha-interferon therapy in chronic HCV hepatitis patients. J Hepatol. 1996; 25(2): 212-7[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments